Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PARADIGM)

stratified for ENCALS risk category [high risk ≥ -4.5 vs. low risk < -4.5], and for background ALS treatment (riluzole and/or edaravone and/or sodium phenylbutyrate and/or taurursodiol) vs. no background

pregnancy testing
weakness
riluzole
edaravone
  • 0 views
  • 07 Jul, 2022
  • 1 location
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA

patients are affected in France. The only therapeutic treatment available to date in France is riluzole, which slows the progression of the disease. Amyotrophic Lateral Sclerosis is the first degenerative

neurological disorder
riluzole
Accepts healthy volunteers
primary lateral sclerosis
  • 0 views
  • 14 Oct, 2021
  • 1 location
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no

weakness
riluzole
progressive disease
primary lateral sclerosis
  • 22 views
  • 09 Apr, 2022
  • 9 locations
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no

riluzole
progressive disease
primary lateral sclerosis
  • 0 views
  • 03 Nov, 2021
  • 17 locations
Arbaclofen in Children and Adolescents With ASD

AIMS-2-CT-01 is a randomized, double-blind, placebo controlled, study to explore the efficacy, safety and tolerability of Arbaclofen administered to children and adolescents (ages 5-17) for the treatment of social adaptive function in participants with ASD. The effects of Arbaclofen on social function in children and adolescents with ASD will be …

seizure
treatment regimen
arbaclofen
autism
antiepileptics
  • 15 views
  • 04 Oct, 2021
  • 7 locations
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial (MICABO-ALS)

The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow …

vitamin e
riluzole
primary lateral sclerosis
  • 0 views
  • 21 Apr, 2022
  • 1 location
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and …

weakness
primary lateral sclerosis
  • 0 views
  • 28 Jun, 2022
  • 1 location
Amyotrophic Lateral Sclerosis and the Innate Immune System

Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it …

respiratory therapy
muscular dystrophy
grave disease
Accepts healthy volunteers
amyotrophic lateral sclerosis
  • 82 views
  • 24 Feb, 2022
  • 6 locations